home / stock / nonof / nonof articles
Novo Nordisk’s (NYSE:NVO) (OTC:NONOF) obesity medication, Wegovy, has been shown to cause more weight loss in women with prevalent heart dise...
Danish biotech company Zealand Pharma A/S (OTC:ZLDPF) has announced encouraging topline results from a Phase 1b multiple ascending dose (MAD) trial...
Patients using Novo Nordisk’s (NYSE:NVO) (OTC:NONOF) obesity treatment, Wegovy, have reportedly maintained an average weight loss of 10% over...
New side effects of the ‘miracle’ weight loss drug Ozempic are emerging, causing concern among patients and healthcare profes...
The family of a man who died by suicide is seeking a warning label on the ‘miracle’ weight loss drug Ozempic, claiming it contributed t...
News, Short Squeeze, Breakout and More Instantly...
Partnership will leverage Aspect’s proprietary bioprinting technology and Novo Nordisk’s expertise and technology in stem cell differentiation and cell therapy development and manufacturing . Aspect to receive 75 million US dollars in initial payments and u...
New York City, NY: May 06, 2020 – Published via (Wired Release):- “Market.us presents a new report titled Alkyl Benzyl Dimethyl Ammonium Chloride Market: 2020 Research and New Innovations in Oil and Gas Sector. The prime objective of the report is to offer updates and information...